Drugs / cinpanemab
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03716570 | Mar 2019 → Apr 2021 | Parkinson disease | Biogen | Terminated | No outcome recorded |
| Phase 1 | NCT02459886 | Jul 2015 → Nov 2017 | Parkinson disease | Biogen | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT03318523 | Jan 2018 → Oct 2020 | Parkinson disease | Biogen | Terminated | Missed primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cinpanemab | “Cinpanemab, a human-derived monoclonal antibody that binds to α-synuclein, is being evaluated as a disease-modifying treatment for Parkinson's disease.” PMID 35921450 ↗ Aug 2022 |
| Known as | BIIB054 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03716570 ↗ |
| Known as | Ni-202 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3833330 ↗ |
| Action | Inhibit | “Alpha-synuclein inhibitor” CHEMBL3833330 ↗ |
| Modality | Monoclonal antibody | “Cinpanemab, a human-derived monoclonal antibody” PMID 35921450 ↗ Aug 2022 |
| Route | Intravenous | “IV infusion” NCT02459886 ↗ |
| Target | SNCA | “Alpha-synuclein inhibitor” CHEMBL3833330 ↗ |